Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma

Weiming Mao, Yang Liu, Robert J. Wordinger, Abbot F. Clark, Iok Hou Pang

Research output: Contribution to journalReview article


Glaucoma is a major cause of blindness in China and the world. Currently, all therapeutic means in treating open-angle glaucoma are limited to control the progression of optic neuropathy by lowering intraocular pressure (IOP). Clinically available medicines lower IOP by either enhancing the uveoscleral pathway or inhibiting aqueous humor production. Since the primary cause of IOP elevation in POAG is elevated outflow resistance in the trabecular outflow pathway, current medicines are not able to correct the underlying pathogenesis and pathophysiology of the disease. In this review article, we discuss a series of new therapeutic targets and therapeutic approaches that are designed to directly modify the pathological changes related to the reduction in trabecular outflow in glaucoma patients. Some of these targets and approaches may produce a significant breakthrough in the treatment of this devastating disease.

Original languageEnglish (US)
Pages (from-to)471-475
Number of pages5
JournalChinese Journal of Ophthalmology
Issue number6
StatePublished - Jun 11 2016
Externally publishedYes


  • Drug discovery
  • Glaucoma, open-angle
  • Molecular targeted therapy
  • Trabecular meshwork

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma'. Together they form a unique fingerprint.

  • Cite this